A novel potassium channel opener for spontaneous preterm birth prevention: Bringing the concepts together

Clin Ter. 2025;176(3):278-283. doi: 10.7417/CT.2025.5222.

Abstract

Aim: Its goal is to evaluate nicorandil, a potassium channel opener, for tocolysis in premature labor patients in a tertiary care facility.

Patients and methods: We evaluated 100 pregnant women who were given nicorandil (study group n= 50 cases) and nifedipine (control group n= 50 cases) for tocolysis in established preterm labour between 24 and 33+6 weeks of gestation. The effectiveness of tocolysis in extending pregnancy for more than 48 hours and 7 days, adverse effects on the mother and fetus, and admission to the neonatal critical care unit were compared across the groups.

Results: The number of births at 24 0/7- 33 6/7 weeks did not differ significantly between the two groups when pregnancy was prolonged for more than 48 hours or 7 days (P > 0.05). Negative effects on the mother and fetus were lower in the nicorandil group (< P 0.05), although both groups' rates of newborn ICU hospitalization were comparable (P > 0.05).

Conclusion: Nicorandil has the benefit of having less harmful effects on the mother and fetus than nifedipine in situations of established preterm labor for inhibiting labor.

Keywords: nicorandil; potassium channel opener; spontaneous preterm birth.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Female
  • Humans
  • Infant, Newborn
  • Nicorandil* / adverse effects
  • Nicorandil* / therapeutic use
  • Nifedipine / adverse effects
  • Nifedipine / therapeutic use
  • Obstetric Labor, Premature* / drug therapy
  • Obstetric Labor, Premature* / prevention & control
  • Potassium Channels* / drug effects
  • Pregnancy
  • Premature Birth* / prevention & control
  • Tocolysis* / methods
  • Tocolytic Agents* / therapeutic use

Substances

  • Nifedipine
  • Tocolytic Agents
  • Nicorandil
  • Potassium Channels